GoKawiilNovartis agreed to buy Excellergy, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
Novartis to Buy Biotech Excellergy for Up to $2 Billion
Why This Matters
Novartis's acquisition of Excellergy marks a strategic move to strengthen its position in immunology, particularly in innovative treatments for food allergies and related conditions. This deal highlights the ongoing trend of major pharma companies investing heavily in biotech startups to accelerate drug development and diversify their portfolios. For consumers, this could mean access to more advanced and targeted therapies in the future.
Key Takeaways
- Novartis is expanding its immunology portfolio through biotech acquisitions.
- The deal emphasizes the growing importance of biotech startups in drug innovation.
- Patients may benefit from new, targeted treatments for food allergies and immune-related diseases.
Get alerts for these topics